GlassScriptPhysician profile
Kami O Moore
NPI 1639390768
$2,970.45
in general payments reported to CMS, 2019-2025
27 companies · $606 in 2025
The $606 reported for 2025 was more than what 76% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $688 · 2023: $764 · 2024: $586 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,955.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $401.14 | 2022-2025 | Verquvo, Capvaxive, Belsomra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $357.90 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $324.59 | 2023-2025 | |
| Pfizer INC. | $271.91 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $226.68 | 2021-2025 | Eliquis |
| Abiomed | $223.63 | 2024-2025 | Impella |
| Amgen INC. | $201.78 | 2021-2024 | Repatha |
| Medtronic, INC. | $153.67 | 2022-2024 | Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $108.06 | 2021-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $89.85 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $77.40 | 2021-2024 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $75.13 | 2021-2023 | Opsumit |
| Cvrx, INC. | $57.07 | 2024-2025 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $53.44 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $48.31 | 2023 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $41.97 | 2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $35.82 | 2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $32.63 | 2022-2023 | Watchman Flx |
| Irhythm Technologies, INC. | $26.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.18 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $24.42 | 2023 | Onpattro |
| Abbott Laboratories | $22.17 | 2022 | |
| Inspire Medical Systems, INC. | $21.88 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $21.70 | 2022 | |
| Amarin Pharma, INC. | $18.38 | 2021 | |
| Esperion Therapeutics, INC. | $13.97 | 2021 | |
| Philips North America LLC | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kami Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.